{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039035","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2023-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.416511+00:00","generated_at":"2026-06-12T04:17:28.446757+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Axsome Q2 product revenue $46.7M; Auvelity sales $27.6M, up 76% sequentially","bullets":["Total product revenue $46.7M vs $8.8M in Q2 2022 (Auvelity $27.6M, Sunosi $19.1M).","Net loss $67.2M ($1.54/share) vs $41.4M loss in prior year; cash $437.1M at June 30, 2023.","Expanding Auvelity sales force from 162 to 260 reps to reach 44,000 physicians.","Initiated FOCUS Phase 3 trial of solriamfetol in ADHD; plans Phase 3 trials in binge eating (Q4 2023) and shift work disorder (Q1 2024).","Anticipates AXS-12 narcolepsy Phase 3 topline in Q4 2023 and AXS-05 Alzheimer's agitation data in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039035","json":"https://secwatch.observer/filing/0000950170-23-039035.json","markdown":"https://secwatch.observer/filing/0000950170-23-039035.md","text":"https://secwatch.observer/filing/0000950170-23-039035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023039035/0000950170-23-039035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023039035/axsm-20230807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T04:17:28.446757+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0aec47e2eb5273808e0283b27e6f4d30e8314ba2","claim":"Axsome Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $46.7 million, net income $(1.54) per share.","evidence_excerpt":"--- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Total 2Q 2023 product revenue of $46.7 million Auvelity ® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi ® 2Q 2023 net product revenue of $19.1 million Pro forma second quarter","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000095017023039035/0000950170-23-039035-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$46.7 million"},{"label":"Net income","value":"$(1.54) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}